00:27 , Jun 22, 2019 |  BC Extra  |  Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

Cotellic/Tecentriq combo misses in melanoma  Exelixis Inc. (NASDAQ:EXEL) revealed in a Thursday SEC filing that Cotellic cobimetinib plus Tecentriq atezolizumab from partner Genentech Inc. missed the primary endpoint of improving progression-free survival vs. Keytruda pembrolizumab...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
20:38 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

Cancer Prevention Pharmaceuticals Inc. (Tucson, Ariz.) said an IDMC recommended continuation of the Phase III CPP FAP-310 trial evaluating eflornithine/sulindac (DFMO/sulindac, CPP-1X/sulindac) to treat familial adenomatous polyposis (FAP). The product is a combination of eflornithine...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Eflornithine/sulindac: Completed Phase III enrollment

Cancer Prevention completed enrollment of 166 FAP patients in a double-blind, placebo-controlled, international Phase III trial comparing 750 mg oral eflornithine once daily plus 150 mg oral sulindac once daily vs. each of its components...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Cancer Prevention Pharmaceuticals, Sucampo deal

Cancer Prevention granted Sucampo an exclusive option to exclusively develop and commercialize CCP-1X/sulindac in North America. Cancer Prevention will complete the ongoing Phase III trial of CPP-1X/sulindac to treat familial adenomatous polyposis (FAP) under a...
07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Arginase 1 (ARG1)

Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest inhibiting arginase could help treat AD. In pathological brain tissue of a mouse model of AD, levels of ARG1 were higher and levels of arginine were lower...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

Cancer Prevention Pharmaceuticals, Zeria deal

Cancer Prevention granted Zeria's Tillotts Pharma AG subsidiary exclusive rights to develop and commercialize CPP-1X/sulindac in Europe and Japan to treat familial adenomatous polyposis (FAP). Cancer Prevention is eligible to receive over $100 million in...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

DFMO/sulindac: Phase III started

Cancer Prevention began a double-blind, placebo-controlled, international Phase III trial to compare 750 mg oral eflornithine once daily plus 150 mg oral sulindac once daily vs. eflornithine or sulindac as single agents for 2 years...